Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Investing Activities (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Cash from Investing Activities for 13 consecutive years, with $90.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 283.24% year-over-year to $90.1 million, compared with a TTM value of $377.2 million through Dec 2025, up 3.78%, and an annual FY2025 reading of $377.2 million, up 3.78% over the prior year.
  • Cash from Investing Activities was $90.1 million for Q4 2025 at Agios Pharmaceuticals, down from $95.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $1.9 billion in Q1 2021 and bottomed at -$2.1 billion in Q2 2021.
  • Average Cash from Investing Activities over 5 years is $33.5 million, with a median of $80.9 million recorded in 2022.
  • Peak annual rise in Cash from Investing Activities hit 1628.95% in 2021, while the deepest fall reached 9564.35% in 2021.
  • Year by year, Cash from Investing Activities stood at -$94.4 million in 2021, then surged by 187.85% to $83.0 million in 2022, then increased by 15.14% to $95.5 million in 2023, then plummeted by 151.47% to -$49.2 million in 2024, then skyrocketed by 283.24% to $90.1 million in 2025.
  • Business Quant data shows Cash from Investing Activities for AGIO at $90.1 million in Q4 2025, $95.6 million in Q3 2025, and $79.0 million in Q2 2025.